Duration of Correction for Human Immunodeficiency Virus-Associated Lipoatrophy After Retreatment with Injectable Poly-l-Lactic Acid

被引：13
|
作者：
Mest, D. R. [1 ]
Humble, G. M. [1 ]
机构：
[1] Blue Pacific Aesthet Med Grp Inc, El Segundo, CA 90245 USA
来源：
AESTHETIC PLASTIC SURGERY | 2009年 / 33卷 / 04期
关键词：
Blue Pacific; Duration; Facial lipoatrophy; Poly-L-lactic acid; Retreatment; FACIAL LIPOATROPHY; EFFICACY; SAFETY; INJECTIONS;
D O I：
10.1007/s00266-008-9226-7
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The Blue Pacific study assessed the effect of injectable poly-l-lactic acid (PLLA) (Sculptra; Dermik Laboratories, a business of Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA) for the treatment of human immunodeficiency virus (HIV)-associated facial lipoatrophy. This case report describes a patient treated originally with injectable PLLA in the Blue Pacific study, then retreated with injectable PLLA 12 months after completion of his initial treatment sessions. Retreatment was well tolerated and resulted in a correction of facial lipoatrophy for a duration of 2 years 7 months.
引用
收藏
页码：654 / 656
页数：3
相关论文
共 50 条
  • [1] Duration of Correction for Human Immunodeficiency Virus-Associated Lipoatrophy After Retreatment with Injectable Poly-l-Lactic Acid
    D. R. Mest
    G. M. Humble
    Aesthetic Plastic Surgery, 2009, 33 : 654 - 656
  • [2] Injectable Poly-L-Lactic Acid for Human Immunodeficiency Virus-Associated Facial Lipoatrophy: Cumulative Year 2 Interim Analysis of an Open-Label Study (FACES)
    Bassichis, Benjamin
    Blick, Gary
    Conant, Marcus
    Condoluci, David
    Echavez, Michael
    Eviatar, Joseph
    Gold, Michael H.
    Hamilton, Tiffani
    Hanke, C. William
    Humble, Gail
    LaMarca, Anthony
    Daro-Kaftan, Elizabeth
    Mest, Douglas
    Pierone, Gerald
    DERMATOLOGIC SURGERY, 2012, 38 (07) : 1193 - 1205
  • [3] Efficacy and impact of retreatment with poly-L-lactic acid in persons with HIV-associated facial lipoatrophy
    Mest, Douglas R.
    Humble, Gail
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB34 - AB34
  • [4] Retreatment with Injectable Poly-l-Lactic Acid for HIV-Associated Facial Lipoatrophy: 24-Month Extension of the Blue Pacific Study
    Mest, Douglas R.
    Humble, Gail M.
    DERMATOLOGIC SURGERY, 2009, 35 (01) : 350 - 359
  • [5] Facial volumetic correction with injectable poly-L-lactic acid
    Vleggaar, D
    DERMATOLOGIC SURGERY, 2005, 31 (11) : 1511 - 1518
  • [6] Poly-L-lactic acid for facial lipoatrophy in HIV
    El-Beyrouty, Claudine
    Huang, Vanthida
    Darnold, Courtney J.
    Clay, Patrick G.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (09) : 1602 - 1606
  • [7] Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy
    Wildemore, John K.
    Jones, Derek H.
    DERMATOLOGIC SURGERY, 2006, 32 (11) : 1407 - 1409
  • [8] Compositions of injectable poly-d,l-lactic acid and injectable poly-l-lactic acid
    Chen, S. Y.
    Lin, J. Y.
    Lin, C. Y.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020, 45 (03) : 347 - 348
  • [9] Angioedema after Treatment with Injectable Poly-L-Lactic Acid (Sculptra)
    Guardiani, Elizabeth
    Davison, Steven P.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2012, 129 (01) : 187E - 189E
  • [10] Poly-l-Lactic Acid for Correction of Localized Facial Lipoatrophy in an Otherwise Healthy Young Woman
    Burgess, Cheryl M.
    DERMATOLOGIC SURGERY, 2009, 35 (05) : 881 - 884
12345